Publicaciones en colaboración con investigadores/as de Dana–Farber Cancer Institute (26)

2023

  1. Generation of mouse models carrying B cell restricted single or multiplexed loss-of-function mutations through CRISPR-Cas9 gene editing

    STAR Protocols, Vol. 4, Núm. 4

  2. In Vivo Modeling of CLL Transformation to Richter Syndrome Reveals Convergent Evolutionary Paths and Therapeutic Vulnerabilities

    Blood cancer discovery, Vol. 4, Núm. 2, pp. 150-169

  3. Loss-of-function lesions impact B-cell development and fitness but are insufficient to drive CLL in mouse models

    Blood Advances, Vol. 7, Núm. 16, pp. 4514-4517

2021

  1. Biological significance of monoallelic and biallelic BIRC3 loss in del(11q) chronic lymphocytic leukemia progression

    Blood Cancer Journal, Vol. 11, Núm. 7

  2. ERK inhibitor LY3214996-based treatment strategies for RAS-driven lung cancer

    Molecular Cancer Therapeutics, Vol. 20, Núm. 4, pp. 641-654

  3. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

  4. Pathogenetic and prognostic implications of increased mitochondrial content in multiple myeloma

    Cancers, Vol. 13, Núm. 13

2020

  1. CRISPR/Cas9-generated models uncover therapeutic vulnerabilities of del(11q) CLL cells to dual BCR and PARP inhibition

    Leukemia, Vol. 34, Núm. 6, pp. 1599-1612

  2. Chronic lymphocytic leukemia patients with IGH translocations are characterized by a distinct genetic landscape with prognostic implications

    International Journal of Cancer, Vol. 147, Núm. 10, pp. 2780-2792

  3. High throughput single-cell detection of multiplex CRISPR-edited gene modifications

    Genome Biology, Vol. 21, Núm. 1

2019

  1. DNA damage response-related alterations define the genetic background of patients with chronic lymphocytic leukemia and chromosomal gains

    Experimental Hematology, Vol. 72, pp. 9-13

  2. Dual PAK4-NAMPT inhibition impacts growth and survival, and increases sensitivity to DNA-damaging agents in Waldenstrom € macroglobulinemia

    Clinical Cancer Research, Vol. 25, Núm. 1, pp. 369-377

  3. Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies

    Cancer Cell, Vol. 36, Núm. 4, pp. 369-384.e13

2017

  1. Adaptation of HIV-1 to cells with low expression of the CCR5 coreceptor

    Virology, Vol. 508, pp. 90-107

  2. Residues in the gp41 ectodomain regulate HIV-1 envelope glycoprotein conformational transitions induced by gp120-directed inhibitors

    Journal of Virology, Vol. 91, Núm. 5

2016

  1. Characterization of two distinct early post-entry blocks to HIV-1 in common marmoset lymphocytes

    Scientific Reports, Vol. 6

  2. Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356

    Autophagy

  3. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

    Autophagy, Vol. 12, Núm. 1, pp. 1-222

  4. Role of Mitochondrial Complex IV in Age-Dependent Obesity

    Cell Reports, Vol. 16, Núm. 11, pp. 2991-3002

2015

  1. Autophagy in malignant transformation and cancer progression

    EMBO Journal, Vol. 34, Núm. 7, pp. 856-880